Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-04-05
2005-04-05
McKenzie, Thomas C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S318000, C514S342000, C544S364000, C546S193000, C546S270700
Reexamination Certificate
active
06875767
ABSTRACT:
The present invention relates to compounds having the formula I:which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions. The compounds of the present invention are useful in treating angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
REFERENCES:
patent: 4649146 (1987-03-01), Takaya et al.
patent: 4788195 (1988-11-01), Torley et al.
patent: 4876252 (1989-10-01), Torley et al.
patent: 5463071 (1995-10-01), Himmelsbach et al.
patent: 5516775 (1996-05-01), Zimmermann et al.
patent: 5521184 (1996-05-01), Zimmermann
patent: 5530000 (1996-06-01), Sanfilippo et al.
patent: 5863924 (1999-01-01), Berger et al.
patent: 5952331 (1999-09-01), Berger et al.
patent: 5958934 (1999-09-01), Berger et al.
patent: 6586423 (2003-07-01), Bilodeau et al.
patent: 6586424 (2003-07-01), Bilodeau et al.
patent: 19548415 (1995-12-01), None
patent: 19824175 (1998-05-01), None
patent: 0 384 250 (1990-08-01), None
patent: 0 564 409 (1993-10-01), None
patent: 6475475 (1989-03-01), None
patent: 7149745 (1995-06-01), None
patent: WO 9401423 (1994-01-01), None
patent: WO 9509847 (1995-04-01), None
patent: WO 9509852 (1995-04-01), None
patent: WO 9535275 (1995-12-01), None
patent: WO 9535276 (1995-12-01), None
patent: WO 9719065 (1997-05-01), None
patent: WO9744326 (1997-11-01), None
patent: WO 9964418 (1999-12-01), None
patent: WO 9965884 (1999-12-01), None
patent: WO 0009495 (2000-02-01), None
patent: WO 0012497 (2000-03-01), None
patent: WO 0062778 (2000-10-01), None
Rosen LS., Hematol Oncol Clin North Am. 2002 Oct.; 16(5):1173-87., Medline Abstract PMID: 12512388.*
Wedge, S.R. et al, Cancer Research 60, 970-975, Feb. 15, 2000.*
Lutton, A. et al, Annals of the New York Academy of Sciences 979:80-93 (2002).*
Oncogene, vol. 5, pp. 519-524 (1990), by M. Shibuya, et al.
FEBS Letters, vol. 473, pp. 161-164 (2000), by M. Nakagawa, et al.
Stem Cells, vol. 12, pp. 1-6 (1994), by T. R. Burke, Jr.
Molecular Cell, vol. 4, pp. 915-924 (1999), by B. Eliceiri, et al.
Oncogene, vol. 6, pp. 1677-1683 (1991), by B. Terman, et al.
Nature Medicine, vol. 5, No. 6, pp. 623-628 (1999), by H. Gerber, et al.
Nature Biotech., vol. 17, pp. 963-968 (1999), by V. Brower.
J. of Clin. Investigation, vol. 104, No. 11, pp. 1613-1620 (1999), by N. van Bruggen, et al.
Drug News Perspect, vol. 11, No. 5, pp. 265-270 (1998), by D. A. Greenberg.
Nature, vol. 407, pp. 242-248 (2000), by G. Yancopoulos, et al.
Nature, vol. 407, pp. 249-257 (2000), by P. Carmeliet, et al.
Platelets, vol. 10, pp. 285-292 (1999), by A. Amirkhosravi, et al.
Endocrinology, Abstract, vol. 141, No. 5, pp. 1667-1674 (2000), by M. Deckers, et al.
Chem. Abst., vol. 109, No. 8, p. 634 (1988), N. A. Shvink.
Chem. Abstr., vol. 111, No. 15 (1989), by M. Tsuji.
Chem. Abstr., vol. 111, No. 21 (1989), by M. Santus.
Chem. Abstr., vol. 126, No. 21 (1997), by C. S. Ra.
Chem. Abstr., vol. 101, No. 11 (1984), by H. Nagatomi.
Abstract, Indiana J. Chem., Sect. G (1986), 25B(4), 452-5, S.E. Kulkarni, et al.
Abstract, Eur. Pat. Appl., 35 pp., T. Takaya, et al.
Abstract, Acta Pol. Pharm. (1980), 37(3), 293-300, M. Santus.
Abstract, Res. Commun., (1982), 14(4), 359-68, M. Tandon, et al.
Abstract, Pharmazie (1975), 30(3), 141-7, G. Wagner, et al.
Annual Reports in Med. Chem., vol. 27, pp. 139-148 (1992), Mitchell, et al.
Bilodeau Mark T.
Hartman George D.
Daniel Mark R.
McKenzie Thomas C.
Merck & Co. , Inc.
Muthard David A.
LandOfFree
(5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3372401